BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80-84. e2. [PMID: 23891927 DOI: 10.1016/j.cgh.2013.07.010] [Cited by in Crossref: 179] [Cited by in F6Publishing: 174] [Article Influence: 22.4] [Reference Citation Analysis]
Number Citing Articles
1 Johnston EL, Warner BD, Digby-Bell JL, Unsworth N, Anderson S, Sanderson JD, Arkir Z, Irving PM. Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterol 2017;8:189-95. [PMID: 28839908 DOI: 10.1136/flgastro-2016-100739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
2 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
3 Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197. [PMID: 25222660 DOI: 10.1097/mib.0000000000000202] [Cited by in Crossref: 100] [Cited by in F6Publishing: 36] [Article Influence: 16.7] [Reference Citation Analysis]
4 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 365] [Article Influence: 166.0] [Reference Citation Analysis]
5 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2019;13:189-197. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
6 Samaan MA, Bagi P, Vande Casteele N, D’haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014;43:479-94. [DOI: 10.1016/j.gtc.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
7 Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300. [PMID: 28839870 DOI: 10.1136/flgastro-2016-100685] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
8 Petitdidier N, Beaugerie L, Carbonnel F, Bourrier A, Treton X, Rajca S, Malamut G, Abitbol V, Allez M, Pelletier AL, Marthey L, Jouet P, Benamouzig R, Amiot X, Bouhnik Y, Amiot A. Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. Clin Res Hepatol Gastroenterol 2020;44:609-18. [PMID: 31924554 DOI: 10.1016/j.clinre.2019.11.008] [Reference Citation Analysis]
9 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Samaan MA, Arkir Z, Ahmad T, Irving PM. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Expert Opin Biol Ther 2018;18:1271-9. [PMID: 30339466 DOI: 10.1080/14712598.2018.1537367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Detrez I, Van Stappen T, Martín Arranz MD, Papamichael K, Gils A. Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease. Ther Drug Monit 2017;39:344-9. [PMID: 28328760 DOI: 10.1097/FTD.0000000000000394] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 5.7] [Reference Citation Analysis]
12 Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2015;21:1709-18. [PMID: 25901974 DOI: 10.1097/MIB.0000000000000380] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
13 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
14 Ward MG, Irving PM, Sparrow MP. How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11331-11342 [PMID: 26525434 DOI: 10.3748/wjg.v21.i40.11331] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Grossberg LB, Papamichael K, Feuerstein JD, Siegel CA, Ullman TA, Cheifetz AS. A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:191-7. [DOI: 10.1093/ibd/izx023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
16 Yamamoto-Furusho JK. Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. Pharmgenomics Pers Med 2017;10:197-204. [PMID: 28603427 DOI: 10.2147/PGPM.S109648] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
17 Berends SE, Strik AS, Van Selm JC, Löwenberg M, Ponsioen CY, D'haens GR, Mathôt RA. Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease. Therapeutic Drug Monitoring 2018;40:202-11. [DOI: 10.1097/ftd.0000000000000494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L. Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease. Inflamm Bowel Dis 2015;21:1047-53. [PMID: 25803504 DOI: 10.1097/MIB.0000000000000359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
20 Jasurda JS, McCabe RP, Vaughn BP. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. Ther Drug Monit 2021;43:645-51. [PMID: 33346627 DOI: 10.1097/FTD.0000000000000849] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378. [PMID: 24595615 DOI: 10.1007/s11894-014-0378-0] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 10.6] [Reference Citation Analysis]
22 Courbette O, Aupiais C, Viala J, Hugot J, Roblin X, Candon S, Louveau B, Chatenoud L, Martinez-vinson C. Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology & Nutrition 2020;70:310-7. [DOI: 10.1097/mpg.0000000000002536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
23 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
24 Borren NZ, Paulides E, Frinack JL, Olson RN, Willrich MAV, van der Woude CJ, Ananthakrishnan AN. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Dig Dis Sci 2020. [PMID: 33037969 DOI: 10.1007/s10620-020-06645-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Freeman K, Taylor-Phillips S, Connock M, Court R, Tsertsvadze A, Shyangdan D, Auguste P, Mistry H, Arasaradnam R, Sutcliffe P, Clarke A. Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis. BMJ Open 2017;7:e014581. [PMID: 28674134 DOI: 10.1136/bmjopen-2016-014581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496 [PMID: 28293096 DOI: 10.3748/wjg.v23.i8.1489] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Duveau N, Nachury M, Gerard R, Branche J, Maunoury V, Boualit M, Wils P, Desreumaux P, Pariente B. Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab. Digestive and Liver Disease 2017;49:163-9. [DOI: 10.1016/j.dld.2016.11.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016;14:550-557.e2. [PMID: 26538204 DOI: 10.1016/j.cgh.2015.10.025] [Cited by in Crossref: 219] [Cited by in F6Publishing: 192] [Article Influence: 36.5] [Reference Citation Analysis]
29 Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. J Crohns Colitis 2019;13:1248-56. [PMID: 30820530 DOI: 10.1093/ecco-jcc/jjz050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
30 Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases. Gastroenterology 2017;153:835-857.e6. [PMID: 28774547 DOI: 10.1053/j.gastro.2017.07.031] [Cited by in Crossref: 149] [Cited by in F6Publishing: 122] [Article Influence: 37.3] [Reference Citation Analysis]
31 Juncadella A, Papamichael K, Vaughn BP, Cheifetz AS. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63:3067-3073. [PMID: 30006816 DOI: 10.1007/s10620-018-5202-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
32 Jossen J, Dubinsky M. Therapeutic drug monitoring in inflammatory bowel disease. Curr Opin Pediatr 2016;28:620-5. [PMID: 27583410 DOI: 10.1097/MOP.0000000000000393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
33 Gofin Y, Matar M, Shamir R, Assa A. Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 2015;13:522-530.e2. [PMID: 25066837 DOI: 10.1016/j.cgh.2014.07.029] [Cited by in Crossref: 189] [Cited by in F6Publishing: 166] [Article Influence: 27.0] [Reference Citation Analysis]
35 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 179] [Article Influence: 35.2] [Reference Citation Analysis]
36 Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol. 2016;7:e135. [PMID: 26741065 DOI: 10.1038/ctg.2015.63] [Cited by in Crossref: 236] [Cited by in F6Publishing: 212] [Article Influence: 47.2] [Reference Citation Analysis]
37 Silva-Ferreira F, Afonso J, Pinto-Lopes P, Magro F. A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays. Inflamm Bowel Dis. 2016;22:2289-2301. [PMID: 27508512 DOI: 10.1097/mib.0000000000000855] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
38 Salvador-Martín S, Pujol-Muncunill G, Bossacoma F, Navas-López VM, Gallego-Fernández C, Segarra O, Clemente S, Muñoz-Codoceo R, Viada J, Magallares L, Martínez-Ojinaga E, Moreno-Álvarez A, Solar-Boga A, Loverdos I, Merino-Bohórquez V, Balboa-Vega MJ, Rodriguez-Martinez A, Alvarez-Vayo C, Sanchez C, Tolin M, Blanca-García JA, García-Romero R, Eizaguirre FJ, Sánchez-Hernandez JG, de Caldas RG, Millán-Jimenez A, Aznal E, Abarca-Zabalía J, Sanjurjo-Sáez M, López-Fernández LA. Pharmacogenetics of trough serum anti-TNF levels in paediatric inflammatory bowel disease. Br J Clin Pharmacol 2021;87:447-57. [PMID: 32478906 DOI: 10.1111/bcp.14400] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, Gils A, Ferrante M. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. J Crohns Colitis. 2017;11:53-59. [PMID: 27402915 DOI: 10.1093/ecco-jcc/jjw122] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
40 Assa A, Matar M, Turner D, Broide E, Weiss B, Ledder O, Guz-mark A, Rinawi F, Cohen S, Topf-olivestone C, Shaoul R, Yerushalmi B, Shamir R. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn’s Disease Compared With Reactive Monitoring. Gastroenterology 2019;157:985-996.e2. [DOI: 10.1053/j.gastro.2019.06.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 56] [Article Influence: 36.0] [Reference Citation Analysis]
41 Zittan E, Kabakchiev B, Milgrom R, Nguyen GC, Croitoru K, Steinhart AH, Silverberg MS. Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis. 2016;10:510-515. [PMID: 26783345 DOI: 10.1093/ecco-jcc/jjw014] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 13.2] [Reference Citation Analysis]
42 Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther 2019;49:408-18. [PMID: 30663076 DOI: 10.1111/apt.15113] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
43 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
44 Sorrentino D, Nguyen V, Henderson C, Bankole A. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link. Inflamm Bowel Dis. 2016;22:2527-2537. [PMID: 27575494 DOI: 10.1097/mib.0000000000000867] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 4.7] [Reference Citation Analysis]
45 Vaughn BP, Sandborn WJ, Cheifetz AS. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1435-42. [PMID: 25590953 DOI: 10.1097/MIB.0000000000000312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 0.6] [Reference Citation Analysis]
46 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
47 Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol 2016;14:1302-9. [PMID: 27189916 DOI: 10.1016/j.cgh.2016.05.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
48 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Lucafò M, Curci D, Bramuzzo M, Alvisi P, Martelossi S, Silvestri T, Guastalla V, Labriola F, Stocco G, Decorti G. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. Front Pediatr 2021;9:646671. [PMID: 34017806 DOI: 10.3389/fped.2021.646671] [Reference Citation Analysis]
50 Bodini G, Giannini EG, Savarino EV, Savarino V. Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. American Journal of Gastroenterology 2015;110:472-3. [DOI: 10.1038/ajg.2015.10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
51 Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm 2014;2014:172821. [PMID: 24757282 DOI: 10.1155/2014/172821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
52 Aguas Peris M, Bosó V, Navarro B, Marqués-Miñana MR, Bastida G, Beltrán B, Iborra M, Sáez-González E, Monte-Boquet E, Poveda-Andrés JL, Nos P. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflamm Bowel Dis 2017;23:1454-60. [PMID: 28708805 DOI: 10.1097/MIB.0000000000001182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
53 Lin K, Mahadevan U. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring. Gastroenterology Clinics of North America 2014;43:565-79. [DOI: 10.1016/j.gtc.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
54 Lichtenstein GR, Mcgovern DPB. Using Markers in IBD to Predict Disease and Treatment Outcomes: Rationale and a Review of Current Status. Am J Gastroenterol Suppl 2016;3:17-26. [DOI: 10.1038/ajgsup.2016.17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
55 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
56 Mould DR, Dubinsky MC. Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55 Suppl 3:S51-S59. [PMID: 25707964 DOI: 10.1002/jcph.370] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
57 Cherry M, Dutzer D, Nasser Y, Berger AE, Roblin X, Paul S. Point-of-Care Assays Could Be Useful for Therapeutic Drug Monitoring of IBD Patients in a Proactive Strategy with Adalimumab. J Clin Med 2020;9:E2739. [PMID: 32854232 DOI: 10.3390/jcm9092739] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
58 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
59 Papamichael K, Juncadella A, Wong D, Rakowsky S, Sattler LA, Campbell JP, Vaughn BP, Cheifetz AS. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2019;13:976-981. [PMID: 30689771 DOI: 10.1093/ecco-jcc/jjz018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 56.0] [Reference Citation Analysis]
60 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 406] [Article Influence: 123.0] [Reference Citation Analysis]
61 Laserna-mendieta EJ, Salvador-martín S, Arias-gonzález L, Ruiz-ponce M, Menchén LA, Sánchez C, López-fernández LA, Lucendo AJ. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. Clinical Chemistry and Laboratory Medicine (CCLM) 2019;57:1906-14. [DOI: 10.1515/cclm-2019-0202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Nader A, Beck D, Noertersheuser P, Williams D, Mostafa N. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa. Clin Pharmacokinet 2017;56:1091-102. [PMID: 28066879 DOI: 10.1007/s40262-016-0502-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
63 Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Translational Research 2014;163:533-56. [DOI: 10.1016/j.trsl.2014.01.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
64 Sheridan J, Coe CA, Doran P, Egan L, Cullen G, Kevans D, Leyden J, Galligan M, O'Toole A, McCarthy J, Doherty G. Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772). BMJ Open Gastroenterol 2018;5:e000174. [PMID: 29379609 DOI: 10.1136/bmjgast-2017-000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
65 Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol. 2015;55 Suppl 3:S39-S50. [PMID: 25707962 DOI: 10.1002/jcph.374] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
66 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Revista de Gastroenterología de México (English Edition) 2018;83:144-67. [DOI: 10.1016/j.rgmxen.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Davidov Y, Ungar B, Bar-Yoseph H, Carter D, Haj-Natour O, Yavzori M, Chowers Y, Eliakim R, Ben-Horin S, Kopylov U. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. J Crohns Colitis. 2017;11:549-555. [PMID: 28453755 DOI: 10.1093/ecco-jcc/jjw182] [Cited by in Crossref: 16] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
68 Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:482-92. [PMID: 32448898 DOI: 10.1093/ibd/izaa102] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
69 Ungar B, Mazor Y, Weisshof R, Yanai H, Ron Y, Goren I, Waizbard A, Yavzori M, Fudim E, Picard O, Loebstein R, Kopylov U, Dotan I, Chowers Y, Eliakim R, Ben-horin S. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther 2016;43:1293-9. [DOI: 10.1111/apt.13631] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 10.4] [Reference Citation Analysis]
70 Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies: . Inflammatory Bowel Diseases 2016;22:1999-2015. [DOI: 10.1097/mib.0000000000000772] [Cited by in Crossref: 67] [Cited by in F6Publishing: 19] [Article Influence: 13.4] [Reference Citation Analysis]
71 Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res 2017;34:1556-63. [PMID: 28374338 DOI: 10.1007/s11095-017-2150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
72 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017;153:827-834. [PMID: 28780013 DOI: 10.1053/j.gastro.2017.07.032] [Cited by in Crossref: 256] [Cited by in F6Publishing: 205] [Article Influence: 64.0] [Reference Citation Analysis]
74 Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho G, Noble CL, Shand AG, Din S, Arnott ID, Jones GR, Lees CW. Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn’s Disease Are Associated With Biologic Remission. Inflammatory Bowel Diseases 2019;25:1036-43. [DOI: 10.1093/ibd/izy320] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
75 Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients. Dig Dis Sci 2019;64:846-54. [PMID: 30426297 DOI: 10.1007/s10620-018-5362-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
76 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 6.6] [Reference Citation Analysis]
77 Sam MJ, Connor SJ, Ng WW, Toong CM. Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies. Ther Drug Monit 2020;42:821-8. [PMID: 32947553 DOI: 10.1097/FTD.0000000000000795] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Hoseyni H, Xu Y, Zhou H. Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease: An Answer to Optimized Treatment? The Journal of Clinical Pharmacology 2018;58:864-76. [DOI: 10.1002/jcph.1084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
79 Pelletier AL, Nicaise-Roland P. Adalimumab and pharmacokinetics: Impact on the clinical prescription for inflammatory bowel disease. World J Pharmacol 2016; 5(1): 44-50 [DOI: 10.5497/wjp.v5.i1.44] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
80 Sáez Belló M, Llopis Salvia P, Alegre Sancho JJ, Paredes Arquiola JM, Asencio Muñoz MDC, Climente Martí M. Utilidad de las concentraciones séricas de adalimumab como predictores de adherencia al tratamiento. Reumatología Clínica 2020;16:32-7. [DOI: 10.1016/j.reuma.2018.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161 [PMID: 28828193 DOI: 10.4292/wjgpt.v8.i3.155] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
82 Nakamura M, Hirooka Y, Watanabe O, Yamamura T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Goto H. A Retrospective Evaluation of the Utility of Capsule Endoscopy and Double-Balloon Endoscopy in Crohn's Disease. Gastroenterol Res Pract 2016;2016:1085027. [PMID: 26843856 DOI: 10.1155/2016/1085027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
83 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [DOI: 10.1111/apt.15643] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
84 Burnier M. Is There a Threshold for Medication Adherence? Lessons Learnt From Electronic Monitoring of Drug Adherence. Front Pharmacol 2018;9:1540. [PMID: 30687099 DOI: 10.3389/fphar.2018.01540] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
85 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 29] [Article Influence: 53.0] [Reference Citation Analysis]
86 Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.BMC Gastroenterol. 2017;17:97. [PMID: 28789636 DOI: 10.1186/s12876-017-0654-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
87 Bond A, Dodd S, Fisher G, Skouras T, Subramanian S. Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy. Scand J Gastroenterol 2017;52:204-8. [PMID: 27797269 DOI: 10.1080/00365521.2016.1245777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
88 Schäffler H, Geiss D, Gittel N, Rohde S, Huth A, Glass Ä, Brandhorst G, Jaster R, Lamprecht G. Mutations in the NOD2 gene are associated with a specific phenotype and lower anti-tumor necrosis factor trough levels in Crohn's disease. J Dig Dis 2018;19:678-84. [PMID: 30284387 DOI: 10.1111/1751-2980.12677] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
89 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
90 Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study. Inflamm Bowel Dis 2017;23:2048-53. [PMID: 28945636 DOI: 10.1097/MIB.0000000000001223] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
91 Morrison A, Stauffer ME, Kaufman AS. Defining medication adherence in individual patients. Patient Prefer Adherence 2015;9:893-7. [PMID: 26170639 DOI: 10.2147/PPA.S86249] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
92 Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2016;14:543-549. [PMID: 26681486 DOI: 10.1016/j.cgh.2015.11.014] [Cited by in Crossref: 112] [Cited by in F6Publishing: 102] [Article Influence: 18.7] [Reference Citation Analysis]
93 Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250-1256. [PMID: 24913041 DOI: 10.1038/ajg.2014.146] [Cited by in Crossref: 137] [Cited by in F6Publishing: 124] [Article Influence: 19.6] [Reference Citation Analysis]
94 Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R, Geboes K; European Society of Pathology; European Crohn's and Colitis Foundation. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch. 2014;464:511-527. [PMID: 24487791 DOI: 10.1007/s00428-014-1543-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
95 Strik AS, Wang YC, Ruff LE, Yashar W, Messmer BT, Mould DR. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm? AAPS J 2018;20:99. [PMID: 30187153 DOI: 10.1208/s12248-018-0257-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
96 Mostafa NM, Nader AM, Noertersheuser P, Okun M, Awni WM. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2017;31:490-7. [PMID: 27545848 DOI: 10.1111/jdv.13884] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
97 Bourchany A, Gilletta De Saint-Joseph C, Breton A, Barreau F, Mas E. Optimization of biologics to reduce treatment failure in inflammatory bowel diseases. Curr Opin Pharmacol 2020;54:51-8. [PMID: 32947075 DOI: 10.1016/j.coph.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
98 Lie MR, Peppelenbosch MP, West RL, Zelinkova Z, van der Woude CJ. Adalimumab in Crohn’s disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther. 2014;40:1202-1208. [PMID: 25263077 DOI: 10.1111/apt.12969] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
99 Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
100 Rubin DT, Naik S, Kondragunta V, Rao T, Jain A. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay. Curr Med Res Opin 2017;33:837-43. [PMID: 28145781 DOI: 10.1080/03007995.2017.1289908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
101 Jiang W, Li X. Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Mol Diagn Ther 2015;19:141-58. [DOI: 10.1007/s40291-015-0142-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
102 Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017;46:150-61. [PMID: 28481014 DOI: 10.1111/apt.14124] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 11.0] [Reference Citation Analysis]
103 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de Gastroenterología de México 2018;83:144-67. [DOI: 10.1016/j.rgmx.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
104 Mak JW, Sung JJ. The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready? J Gastroenterol Hepatol 2019;34:1269-70. [PMID: 31456235 DOI: 10.1111/jgh.14817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
105 Kato M, Sugimoto K, Ikeya K, Takano R, Matsuura A, Miyazu T, Ishida N, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Hanai H. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. PLoS One 2021;16:e0254548. [PMID: 34242369 DOI: 10.1371/journal.pone.0254548] [Reference Citation Analysis]
106 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 291] [Article Influence: 180.5] [Reference Citation Analysis]
107 Gorovits B, Baltrukonis DJ, Bhattacharya I, Birchler MA, Finco D, Sikkema D, Vincent MS, Lula S, Marshall L, Hickling TP. Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab. Clin Exp Immunol 2018;192:348-65. [PMID: 29431871 DOI: 10.1111/cei.13112] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
108 Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1655-1668.e3. [PMID: 30928454 DOI: 10.1016/j.cgh.2019.03.037] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 43.5] [Reference Citation Analysis]
109 Van den Berghe N, Gils A, Thomas D. Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted? Clin Pharmacol Ther 2019;106:945-54. [PMID: 31420861 DOI: 10.1002/cpt.1609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
110 Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1453-68. [PMID: 32969507 DOI: 10.1111/apt.16096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
111 Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20:1-288. [PMID: 27845027 DOI: 10.3310/hta20830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
112 Sanchez-Hernandez JG, Rebollo N, Munoz F, Martin-Suarez A, Calvo MV. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases. Ann Clin Biochem 2019;56:28-41. [PMID: 29807436 DOI: 10.1177/0004563218782286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
113 Strik AS, Berends SE, Löwenberg M. Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward? Expert Rev Clin Pharmacol 2019;12:885-91. [PMID: 31305158 DOI: 10.1080/17512433.2019.1642745] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
114 Vaughns JD, Conklin LS, Long Y, Zheng P, Faruque F, Green DJ, van den Anker JN, Burckart GJ. Obesity and Pediatric Drug Development. J Clin Pharmacol 2018;58:650-61. [PMID: 29350758 DOI: 10.1002/jcph.1054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
115 Vanga R, Long MD. Contemporary Management of Ulcerative Colitis. Curr Gastroenterol Rep. 2018;20:12. [PMID: 29589185 DOI: 10.1007/s11894-018-0622-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
116 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Rinawi F, Ricciuto A, Church PC, Frost K, Crowley E, Walters TD, Griffiths AM. Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn's Disease. Inflamm Bowel Dis 2021;27:1079-87. [PMID: 32978946 DOI: 10.1093/ibd/izaa247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Vande Casteele N, Khanna R, Levesque BG, Stitt L, Zou GY, Singh S, Lockton S, Hauenstein S, Ohrmund L, Greenberg GR. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn’s disease. Gut. 2015;64:1539-1545. [PMID: 25336114 DOI: 10.1136/gutjnl-2014-307883] [Cited by in Crossref: 186] [Cited by in F6Publishing: 157] [Article Influence: 26.6] [Reference Citation Analysis]
119 Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1288-1295. [PMID: 24831559 DOI: 10.1097/mib.0000000000000037] [Cited by in Crossref: 70] [Cited by in F6Publishing: 26] [Article Influence: 11.7] [Reference Citation Analysis]
120 Deepak P, Bruining DH. Update on the Medical Management of Crohn's Disease. Curr Gastroenterol Rep 2015;17:41. [PMID: 26363802 DOI: 10.1007/s11894-015-0465-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
121 Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2019;25:1532-40. [DOI: 10.1093/ibd/izz003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
122 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
123 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
124 Egan C, Doherty GA. Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment? Expert Opinion on Biological Therapy 2019;19:907-18. [DOI: 10.1080/14712598.2019.1615050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
125 Morita Y, Bamba S, Takahashi K, Imaeda H, Nishida A, Inatomi O, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis. Scand J Gastroenterol 2016;51:934-41. [PMID: 26888161 DOI: 10.3109/00365521.2016.1144781] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
126 Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, Narula N. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients. Eur J Gastroenterol Hepatol 2021;33:1274-9. [PMID: 34402466 DOI: 10.1097/MEG.0000000000002250] [Reference Citation Analysis]
127 Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017;11:35-46. [PMID: 27440869 DOI: 10.1093/ecco-jcc/jjw133] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 13.6] [Reference Citation Analysis]
128 Vasudevan A, Raghunath A, Anthony S, Scanlon C, Sparrow MP, Gibson PR, van Langenberg DR. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn's Disease. Dig Dis Sci 2019;64:1622-31. [PMID: 30560332 DOI: 10.1007/s10620-018-5422-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology 2018;113:890-8. [DOI: 10.1038/s41395-018-0073-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
130 Takeshima F, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Machida H, Matsushima K, Minami H, Akazawa Y, Yamaguchi N, Ohnita K, Isomoto H, Ueno M, Nakao K. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol 2016;16:82. [PMID: 27472988 DOI: 10.1186/s12876-016-0501-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
131 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
132 Lie MRKL, Paulides E, van der Woude CJ. Patient sex does not affect endoscopic outcomes of biologicals in inflammatory bowel disease but is associated with adverse events. Int J Colorectal Dis 2020;35:1489-500. [PMID: 32592091 DOI: 10.1007/s00384-020-03663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. J Crohns Colitis 2019;13:1527-36. [PMID: 31094417 DOI: 10.1093/ecco-jcc/jjz103] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178. [PMID: 26678147 DOI: 10.1186/s12876-015-0408-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
135 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 144] [Cited by in F6Publishing: 117] [Article Influence: 36.0] [Reference Citation Analysis]
136 de Boer NKh, Löwenberg M, Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Clin Exp Gastroenterol 2014;7:83-92. [PMID: 24748811 DOI: 10.2147/CEG.S47627] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
137 Papamichael K, Cheifetz AS. Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease. J Crohns Colitis 2016;10:507-9. [PMID: 26874348 DOI: 10.1093/ecco-jcc/jjw041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
138 Aterido A, Palau N, Domènech E, Nos Mateu P, Gutiérrez A, Gomollón F, Mendoza JL, Garcia-planella E, Barreiro-de Acosta M, Muñoz F, Vera M, Saro C, Esteve M, Andreu M, Chaparro M, Panés J, García-sánchez V, López-lasanta M, Pluma A, Codó L, García-montero A, Manyé J, Gisbert JP, Marsal S, Julià A. Genetic association between CD96 locus and immunogenicity to anti-TNF therapy in Crohn’s disease. Pharmacogenomics J 2019;19:547-55. [DOI: 10.1038/s41397-019-0090-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
139 Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther 2017;45:1135-45. [PMID: 28239869 DOI: 10.1111/apt.13992] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
140 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
141 Ben-Horin S. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time? Gastroenterology. 2015;148:1268-1271. [PMID: 25921372 DOI: 10.1053/j.gastro.2015.04.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
142 Sánchez-Hernández JG, Pérez-Blanco JS, Rebollo N, Muñoz F, Prieto V, Calvo MV. Biomarkers of disease activity and other factors as predictors of adalimumab pharmacokinetics in inflammatory bowel disease. Eur J Pharm Sci 2020;150:105369. [PMID: 32416256 DOI: 10.1016/j.ejps.2020.105369] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
143 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
144 Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther 2018;48:731-9. [PMID: 30109889 DOI: 10.1111/apt.14943] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
145 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
146 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
147 Wilkinson N, Tsakok T, Dand N, Bloem K, Duckworth M, Baudry D, Pushpa-Rajah A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C; BSTOP study group., PSORT consortium. Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. J Invest Dermatol 2019;139:115-23. [PMID: 30130616 DOI: 10.1016/j.jid.2018.07.028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
148 Razvi M, Lazarev M. Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 2017;18:263-72. [DOI: 10.1080/14712598.2018.1410131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
149 Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2015;42:188-202. [PMID: 25996351 DOI: 10.1111/apt.13243] [Cited by in Crossref: 150] [Cited by in F6Publishing: 142] [Article Influence: 25.0] [Reference Citation Analysis]
150 Kim MJ, Kim E, Kang B, Choe YH. Therapeutic Drug Monitoring of Adalimumab During Long-term Follow-up in Paediatric Patients With Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:870-6. [PMID: 33908743 DOI: 10.1097/MPG.0000000000003070] [Reference Citation Analysis]
151 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
152 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
153 Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247 [PMID: 34712029 DOI: 10.3748/wjg.v27.i37.6231] [Reference Citation Analysis]
154 Steenholdt C, Brynskov J, Thomsen OØ, Munck LK, Christensen LA, Pedersen G, Kjeldsen J, Ainsworth MA. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease. J Crohns Colitis 2015;9:1032-42. [PMID: 26245216 DOI: 10.1093/ecco-jcc/jjv139] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
155 Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf 2017;16:303-17. [PMID: 27922765 DOI: 10.1080/14740338.2017.1269169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
156 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 13.8] [Reference Citation Analysis]
157 Feng T, Chen B, Ungar B, Qiu Y, Zhang S, He J, Lin S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25:1813-1821. [PMID: 30934050 DOI: 10.1093/ibd/izz061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
158 Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:1081-6. [DOI: 10.3109/00365521.2016.1157894] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
159 Baert F, Vande Casteele N, Tops S, Noman M, Van Assche G, Rutgeerts P, Gils A, Vermeire S, Ferrante M. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40:1324-1332. [PMID: 25277873 DOI: 10.1111/apt.12968] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
160 Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(9): 886-907 [PMID: 33727776 DOI: 10.3748/wjg.v27.i9.886] [Reference Citation Analysis]
161 Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, Armuzzi A. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy 2015;15:1107-17. [DOI: 10.1517/14712598.2015.1044434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
162 Tighe D, McNamara D. Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease. World J Gastroenterol 2017; 23(3): 414-425 [PMID: 28210077 DOI: 10.3748/wjg.v23.i3.414] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
163 Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016;50:733-741. [PMID: 26535480 DOI: 10.1097/mcg.0000000000000441] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
164 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
165 Naganuma M, Okuda S, Hisamatsu T, Matsuoka K, Mori K, Hosoe N, Nakazato Y, Ogata H, Kanai T. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment. Abdom Radiol (NY) 2017;42:141-51. [PMID: 27549100 DOI: 10.1007/s00261-016-0878-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
166 Heron V, Afif W. Update on Therapeutic Drug Monitoring in Crohn's Disease. Gastroenterol Clin North Am 2017;46:645-59. [PMID: 28838420 DOI: 10.1016/j.gtc.2017.05.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
167 Choi SY, Choi YO, Choe YH, Kang B. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients. J Korean Med Sci 2020;35:e114. [PMID: 32329259 DOI: 10.3346/jkms.2020.35.e114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
168 Boland K, Greener T, Kabakchiev B, Stempak J, Tessolini J, Li R, Soriano J, Croitoru K, Nguyen G, Steinhart AH, Weizman AV, Silverberg MS. Identification of Target Golimumab Levels in Maintenance Therapy of Crohn’s Disease and Ulcerative Colitis Associated With Mucosal Healing. Inflammatory Bowel Diseases 2020;26:766-73. [DOI: 10.1093/ibd/izz199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
169 Morita Y, Imaeda H, Nishida A, Inatomi O, Bamba S, Sasaki M, Tsujikawa T, Sugimoto M, Andoh A. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease. J Gastroenterol Hepatol. 2016;31:1831-1836. [PMID: 27043158 DOI: 10.1111/jgh.13400] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
170 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
171 Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis 2021;27:1346-55. [PMID: 33051647 DOI: 10.1093/ibd/izaa265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Campbell JP, Burton E, Wymer S, Shaw M, Vaughn BP. Out-of-Pocket Cost Is a Barrier to Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3336-43. [PMID: 29052818 DOI: 10.1007/s10620-017-4808-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Sparrow MP. Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target. Expert Opin Biol Ther 2017;17:613-21. [PMID: 28316250 DOI: 10.1080/14712598.2017.1309390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
174 Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-Inhibitors. Front Immunol 2020;11:312. [PMID: 32174918 DOI: 10.3389/fimmu.2020.00312] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]